Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23088633 | 1.00 | DRD2 (0.32) | DRD2HTR2AGRIN2BLPLLIPG | |
| SCHEMBL30712009 | 0.84 | PDE4D (0.40) | — | |
| SCHEMBL23088650 | 0.84 | PDE4D (0.40) | — | |
| SCHEMBL23098518 | 0.83 | PDE4D (0.43) | HTR2ALIPG | |
| SCHEMBL21062063 | 0.74 | PDE4D (0.38) | — | |
| SCHEMBL30712014 | 0.74 | PDE4D (0.38) | — | |
| SCHEMBL23088644 | 0.64 | PDE4D (0.65) | HTR2A | |
| SCHEMBL30712006 | 0.64 | PDE4D (0.65) | HTR2A | |
| SCHEMBL23088646 | 0.64 | PDE4D (0.65) | HTR2A | |
| SCHEMBL23088624 | 0.64 | PDE4D (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400578-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2024-12-05 | — | — | US | disclosed |
| CN-111727191-B | Substituted azetidine dihydro-thienopyridines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400578-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE3A, PDE3B | DRD2 1106/4885HTR2A 500/4885GRIN2B 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.